Ferran Fece de la Cruz
@ferranfececruz.bsky.social
Cancer researcher, Catalan, Instructor @MGHCancerCenter & @harvardmed.bsky.social #CorcoranLab
PhD in Malignant Diseases at @CeMM (Vienna) & @ludwigcancer.bsky.social (Oxford)
PhD in Malignant Diseases at @CeMM (Vienna) & @ludwigcancer.bsky.social (Oxford)
⚠️ #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @mgbresearch.bsky.social @fwf-at.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social #crcsm #lcsm
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in
KRASG12C cancers. However, resistance invariably develops, resulting in short-lived
responses. We aimed to define the ...
www.annalsofoncology.org
February 6, 2025 at 3:31 PM
⚠️ #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @mgbresearch.bsky.social @fwf-at.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social #crcsm #lcsm
I give up 🤦🏻♂️ #TheHandmaidsTale
After White House transition, FDA’s diversity guidance for clinical trials no longer available
The FDA’s guidance detailing diversity action plans for clinical trials that evaluate drugs, devices and other medical products has been taken do | The FDA’s guidance detailing diversity action plans ...
www.fiercebiotech.com
January 28, 2025 at 12:25 AM
I give up 🤦🏻♂️ #TheHandmaidsTale
Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25
dailynews.ascopubs.org/do/pan-ras-i...
dailynews.ascopubs.org/do/pan-ras-i...
January 25, 2025 at 10:46 PM
Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25
dailynews.ascopubs.org/do/pan-ras-i...
dailynews.ascopubs.org/do/pan-ras-i...
Phase 3 #BREAKWATER trial demonstrate a significantly improved response rate that was durable for first-line Encorafenib + Cetuximab + mFOLFOX6 vs. SOC in patients with BRAF V600E mCRC #crcsm #BRAF #GI25 @fightcrc.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
January 25, 2025 at 10:44 PM
Phase 3 #BREAKWATER trial demonstrate a significantly improved response rate that was durable for first-line Encorafenib + Cetuximab + mFOLFOX6 vs. SOC in patients with BRAF V600E mCRC #crcsm #BRAF #GI25 @fightcrc.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
🤯🤯🤯
Site-saturation mutagenesis of 500 human protein domains - Nature
Large-scale experimental analysis of Human Domainome 1, a library containing more than 500,000 missense mutation variants across more than 500 human protein domains, reveals that 60% of pathogenic mis...
www.nature.com
January 8, 2025 at 4:17 PM
🤯🤯🤯
Incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer, and the potential impact on mediating cross-resistance to sequential ADCs! @harvardmed.bsky.social @breastcancernow.bsky.social #CorcoranLab #bcsm #biomarkers #resistance
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer
Abstract. Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of AD...
aacrjournals.org
January 6, 2025 at 8:45 PM
Incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer, and the potential impact on mediating cross-resistance to sequential ADCs! @harvardmed.bsky.social @breastcancernow.bsky.social #CorcoranLab #bcsm #biomarkers #resistance
Great news! #RAS
We’re proud to announce the launch of Center for RAS Therapeutics to target the RAS oncogene in cancer. The first of its kind Center aims to advance new treatment approaches for patients with RAS mutant cancers.
Learn more: https://bit.ly/3BobmtB
Learn more: https://bit.ly/3BobmtB
Center for RAS Therapeutics
The Dana-Farber Center for RAS Therapeutics is a multi-disciplinary initiative that seeks to advance novel treatment approaches to transform the lives of patients with RAS-driven cancers through scientific discovery, translational research, and clinical investigation.
bit.ly
January 6, 2025 at 3:55 PM
Great news! #RAS
December 30, 2024 at 3:51 PM
Reposted by Ferran Fece de la Cruz
Safety and efficacy of the next generation of PI3K targeting agents reviewed @sabcs.bsky.social #SABCS24 poster highlights PS7-01-02-03 @oncoalert.bsky.social
December 11, 2024 at 1:49 PM
Safety and efficacy of the next generation of PI3K targeting agents reviewed @sabcs.bsky.social #SABCS24 poster highlights PS7-01-02-03 @oncoalert.bsky.social
Great news fresh from #SABCS24 RLY-2608 (mutant selective PI3Kα inhibitor):
mPFS 9.2m (all patients)
mPFS 11.4m (for kinase domain mutants H1047R)
Clinical Benefit Rate 67%
#bcsm @breastcancernow.bsky.social
mPFS 9.2m (all patients)
mPFS 11.4m (for kinase domain mutants H1047R)
Clinical Benefit Rate 67%
#bcsm @breastcancernow.bsky.social
December 11, 2024 at 1:21 PM
Great news fresh from #SABCS24 RLY-2608 (mutant selective PI3Kα inhibitor):
mPFS 9.2m (all patients)
mPFS 11.4m (for kinase domain mutants H1047R)
Clinical Benefit Rate 67%
#bcsm @breastcancernow.bsky.social
mPFS 9.2m (all patients)
mPFS 11.4m (for kinase domain mutants H1047R)
Clinical Benefit Rate 67%
#bcsm @breastcancernow.bsky.social
"Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks are still too limited."
Why the genetic-testing revolution left some people behind — and what to do about it
Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks are still too limited.
www.nature.com
December 10, 2024 at 4:23 PM
"Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks are still too limited."
Interesting perspective on key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens @oncoalert.bsky.social #CancerTherapeutics #DrugDevelopment #Synergy
Oncology Combination Drug Development Strategies for Project Optimus
Abstract. The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for s...
aacrjournals.org
December 6, 2024 at 10:19 PM
Interesting perspective on key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens @oncoalert.bsky.social #CancerTherapeutics #DrugDevelopment #Synergy
Reposted by Ferran Fece de la Cruz
Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky
www.targetedonc.com/view/durvalu....
www.targetedonc.com/view/durvalu....
Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.
www.targetedonc.com
December 4, 2024 at 11:51 PM
Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky
www.targetedonc.com/view/durvalu....
www.targetedonc.com/view/durvalu....
"Although the policies of the incoming administration are not yet unsettled, fears and uncertainties can wreak damage on student morale. Check in with the foreign students/fellows in your classes, labs, and institutions." @harvardmed.bsky.social @aclum.bsky.social @academic-chatter.bsky.social
US academics: look after foreign students
The first Trump term took a toll on international scholars and collaborations — we can avoid similar pitfalls.
www.nature.com
December 4, 2024 at 7:30 PM
"Although the policies of the incoming administration are not yet unsettled, fears and uncertainties can wreak damage on student morale. Check in with the foreign students/fellows in your classes, labs, and institutions." @harvardmed.bsky.social @aclum.bsky.social @academic-chatter.bsky.social
⬇️⬇️⬇️
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research.
A Place of Joy.
A Place of Joy.
December 4, 2024 at 4:53 AM
⬇️⬇️⬇️
Ryan Corcoran, MD, PhD, and Aparna Parikh, MD, answer questions about the science behind blood testing to check for remaining cancer cells after surgery #LiquidBiopsy #MRD
www.massgeneralbrigham.org/en/about/new...
www.massgeneralbrigham.org/en/about/new...
Blood Test Detects Residual Cancer After Surgery | Mass General Brigham
Mass General Brigham researchers helped to develop a blood test to detect remaining cancer cells after surgery. Learn more in this Q&A with Dr. Corcoran.
www.massgeneralbrigham.org
December 2, 2024 at 3:58 PM
Ryan Corcoran, MD, PhD, and Aparna Parikh, MD, answer questions about the science behind blood testing to check for remaining cancer cells after surgery #LiquidBiopsy #MRD
www.massgeneralbrigham.org/en/about/new...
www.massgeneralbrigham.org/en/about/new...